Breaking News Instant updates and real-time market news.

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25

Canaccord biotech analyst to hold a dinner meeting

In conjunction with the 58th Annual ASH Meeting, Biotech Analyst Newman hosts a Key Opinion Leader Dinner Meeting with Raajit Rampal, MD, who discusses the implications for Incyte (INCY), Pfizer (PFE) and Eli Lilly (LLY) on December 4 at 8:30 pm.

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

  • 04

    Dec

  • 15

    Dec

INCY Incyte
$102.02

2.09 (2.09%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
RHCO
11/18/16
NO CHANGE
RHCO
Incyte has several positive catalysts, says SunTrust
SunTrust analyst PEter Lawson says he expects Incyte's baricitinib, which he calls a key profitability driver for the company, to be approved by the FDA next quarter. He also expects the company to benefit from positive data on its epacadostat and IOs in solid tumor settings. The analyst keeps a Buy rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
PFE Pfizer
$31.63

0.17 (0.54%)

11/29/16
11/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/16
12/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Exxon Mobil (XOM) initiated at BMO Capital. 2. Pfizer (PFE) initiated with a Neutral at Guggenheim. 3. DuPont Fabros (DFT) initiated with a Neutral at Guggenheim. 4. Acadia (ACHC) resumed with a Buy at Jefferies. 5. Shire (SHPG) initiated with a Buy at Societe Generale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/16
GUGG
12/02/16
INITIATION
GUGG
Neutral
Pfizer initiated with a Neutral at Guggenheim
11/29/16
LEHM
11/29/16
UPGRADE
Target $38
LEHM
Overweight
Pfizer upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Pfizer to Overweight and raised its price target to $38 from $37. Meacham sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders.
LLY Eli Lilly
$67.71

1.74 (2.64%)

11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
12/02/16
EVER
12/02/16
NO CHANGE
EVER
Hold
Eli Lilly expanded indication bodes well for Jardiance growth, says Evercore ISI
Evercore ISI analyst John Scotti said the FDA approval of Jardiance's sNDA for the reduction of CV mortality allows Eli Lilly's salesforce to directly promote the CV death indication, which he believes bodes well for the growth of the Jardiance franchise. The company, which has maintained that updates to the label and treatment guidelines expected in 2017 are likely to cause an inflection in the drug's sales, said the updated label should be on-line by next week, added Scotti, who has a Hold rating on Lilly shares.
12/02/16
GSCO
12/02/16
NO CHANGE
Target $82
GSCO
Buy
Jardiance CV death risk reduction indication a positive for Lilly, says Goldman
Goldman Sachs analyst Jami Rubin said his estimate, and the current consensus estimate, for Jardiance sales assumed that Eli Lilly (LLY) would get a new indication for Jardiance to reduce the risk of cardiovascular death in type 2 diabetes patients, but he still views the news as positive for sentiment given some investor nervousness and the recent solanezumab disappointment. The indication differentiates Jardiance from Johnson & Johnson's (JNJ) Invokana and AstraZeneca's (AZN) Farxiga, adds Rubin, who has a Buy rating and $82 price target on Lilly shares.
11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.

TODAY'S FREE FLY STORIES

MDC

M.D.C. Holdings

$31.73

0.11 (0.35%)

17:10
09/21/17
09/21
17:10
09/21/17
17:10
Hot Stocks
M.D.C. Holdings announces Richmond American Homes enters Oregon Market »

M.D.C. Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

17:09
09/21/17
09/21
17:09
09/21/17
17:09
Hot Stocks
Versartis down 85% after Phase 3 of somavaratan did not meet primary endpoint »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IART

Integra LifeSciences

$48.31

-0.58 (-1.19%)

17:05
09/21/17
09/21
17:05
09/21/17
17:05
Hot Stocks
Integra LifeSciences enrolls first patient in Cadence ankle system study »

Integra LifeSciences has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TIF

Tiffany

$89.85

-0.08 (-0.09%)

, RL

Ralph Lauren

$88.48

-0.63 (-0.71%)

17:04
09/21/17
09/21
17:04
09/21/17
17:04
Hot Stocks
Tiffany names Roger Farah as Chairman of Board, effective October 2 »

Tiffany & Co. (TIF)…

TIF

Tiffany

$89.85

-0.08 (-0.09%)

RL

Ralph Lauren

$88.48

-0.63 (-0.71%)

M

Macy's

$21.16

-0.32 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

VSAR

Versartis

$21.60

-0.25 (-1.14%)

17:00
09/21/17
09/21
17:00
09/21/17
17:00
Hot Stocks
Breaking Hot Stocks news story on Versartis 

Versartis trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

$42.19

-0.19 (-0.45%)

16:57
09/21/17
09/21
16:57
09/21/17
16:57
Hot Stocks
Flowserve appoints Lee Eckert as CFO »

Flowserve has named Lee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$60.50

0.38 (0.63%)

16:57
09/21/17
09/21
16:57
09/21/17
16:57
Periodicals
Regulators weigh removing SIFI 'tag' from insurer AIG, Dow Jones says »

According to the report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$34.94

-0.06 (-0.17%)

16:54
09/21/17
09/21
16:54
09/21/17
16:54
Hot Stocks
Aecom announces capital allocation policy and $1B stock repurchase authorization »

Aecom announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALOG

Analogic

$79.95

2.35 (3.03%)

16:49
09/21/17
09/21
16:49
09/21/17
16:49
Hot Stocks
Analogic achieves ECAC standard C2 for new cabin baggage screening solution »

Analogic announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$69.50

-0.45 (-0.64%)

16:39
09/21/17
09/21
16:39
09/21/17
16:39
Earnings
Compass Minerals lowers FY17 EPS view to $2.50-$2.80 from $3.00-$3.50 »

Consensus is $3.02. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

MDU

MDU Resources

$26.21

-0.19 (-0.72%)

16:39
09/21/17
09/21
16:39
09/21/17
16:39
Hot Stocks
MDU Resources names Jason Vollmer CFO, Stephanie Barth CAO »

MDU Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:36
09/21/17
09/21
16:36
09/21/17
16:36
General news
Money Supply M2 Weekly Change data reported »

Week of 9/11 Money Supply…

16:36
09/21/17
09/21
16:36
09/21/17
16:36
General news
Fed Balance Sheet Level data reported »

Week of 9/20 Fed Balance…

TXN

Texas Instruments

$86.05

0.22 (0.26%)

16:35
09/21/17
09/21
16:35
09/21/17
16:35
Hot Stocks
Texas Instruments raises dividend 24%, adds to repurchase program »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

16:34
09/21/17
09/21
16:34
09/21/17
16:34
Hot Stocks
Versartis' somavaratan did not meet primary endpoint in Phase 3 trial »

Versartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$90.44

-1.51 (-1.64%)

, DWDP

DowDuPont

$70.32

-0.09 (-0.13%)

16:34
09/21/17
09/21
16:34
09/21/17
16:34
Hot Stocks
FMC Corporation cleared for proposed acquisition of DuPont Crop Protection unit »

FMC Corporation (FMC)…

FMC

FMC Corporation

$90.44

-1.51 (-1.64%)

DWDP

DowDuPont

$70.32

-0.09 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MCD

McDonald's

$159.03

-0.85 (-0.53%)

16:32
09/21/17
09/21
16:32
09/21/17
16:32
Hot Stocks
McDonald's increases quarterly dividend 7% »

McDonald's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

16:30
09/21/17
09/21
16:30
09/21/17
16:30
Options
Preliminary option volume of 13.2M today »

Preliminary option volume…

TGI

Triumph Group

$27.85

-0.2 (-0.71%)

, BA

Boeing

$256.04

0.58 (0.23%)

16:27
09/21/17
09/21
16:27
09/21/17
16:27
Hot Stocks
Triumph Group signs contract extensions with Boeing for ducting, floor panels »

Triumph Group (TGI)…

TGI

Triumph Group

$27.85

-0.2 (-0.71%)

BA

Boeing

$256.04

0.58 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

16:25
09/21/17
09/21
16:25
09/21/17
16:25
Earnings
YogaWorks sees Q3 revenue $12.7M-$13.2M, consensus $12.9M »

For the third quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VSAR

Versartis

$21.60

-0.25 (-1.14%)

16:25
09/21/17
09/21
16:25
09/21/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Versartis »

Versartis trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

16:22
09/21/17
09/21
16:22
09/21/17
16:22
Earnings
YogaWorks reports Q2 adjusted net loss $3.1M vs. adjusted net loss $2.7M in Q216 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

CSII

Cardiovascular Systems

$27.63

0.38 (1.39%)

16:20
09/21/17
09/21
16:20
09/21/17
16:20
Initiation
Cardiovascular Systems initiated  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
09/21/17
09/21
16:20
09/21/17
16:20
Options
Closing CBOE SPX and VIX Index summary for September 21st »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$11.45

0.01 (0.09%)

16:18
09/21/17
09/21
16:18
09/21/17
16:18
Syndicate
Breaking Syndicate news story on Immunomedics »

Immunomedics files 34.8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.